An unexpected finding of apparent bilateral aldosterone suppression after superselective adrenal venous sampling: a case report.

Blood PressJun 1, 2026 (epub)
Case ReportEndocrinology

Xiaoxi Pan, Yu Ma, Yuanyuan Kang et al.

✦ AI-curated · Sources linked

Case in brief

A 40-year-old man with hypertension and refractory hypokalaemia was found to have a right adrenal adenoma. Initial adrenal venous sampling (AVS) showed apparent bilateral aldosterone suppression (ABAS), complicating the diagnosis of primary aldosteronism. A repeat AVS revealed different venographic patterns, confirming right-sided aldosterone excess. Following right adrenalectomy, the patient achieved clinical and biochemical remission, with histological confirmation of an aldosterone-producing adenoma.

What made this case unusual

The case illustrates the diagnostic challenge of ABAS during AVS, where different catheter positions can lead to misleading results regarding aldosterone secretion.

Diagnostic / clinical pearl

Clinicians should be aware that apparent bilateral aldosterone suppression does not rule out unilateral primary aldosteronism, and careful sampling from the main adrenal vein trunk is essential for accurate diagnosis.

Why it matters

This case emphasizes the importance of understanding the potential pitfalls in adrenal venous sampling techniques, which can significantly impact the management of patients with suspected primary aldosteronism.

Source

Published in Blood Press. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.